Status:
COMPLETED
Gardasil Versus Cervarix in the Treatment of Warts
Lead Sponsor:
Zagazig University
Conditions:
Verruca Viral
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Warts are common, benign, epidermal proliferations caused by HPV infecting skin and mucous membranes. Treatment of warts poses a true challenge despite existing variable therapeutic modalities, whethe...
Detailed Description
Approximately 35% of viral warts tend to be recalcitrant either showing no response to treatment or having prompt recurrences after treatment, causing frustration for both patients and physicians. Suc...
Eligibility Criteria
Inclusion
- Adult Patients with recalcitrant multiple warts of any type. Warts were considered recalcitrant if they persisted for at least 6 months without any response to 2 different therapeutic modalities or more.
- Immunocompetent patients.
- Patients who do not receive any treatment of warts for at least 1 month before the start of study.
- Patients who are able to understand and follow the study protocol and approve to sign the informed consent
Exclusion
- Patients with acute febrile illness.
- Past history of asthma.
- Allergic skin disorders, such as generalized eczema, or severe urticaria.
- Pregnancy or lactation
- History of hypersensitivity to the treatment vaccines.
- Children
- Immunocompromised patients
- Patients unable to follow the study protocol
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05383625
Start Date
September 1 2020
End Date
December 1 2021
Last Update
May 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University
Zagazig, Select Region, Egypt, 44511